# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:TECH) with a Buy and maintains $95 price target.
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $73 to...
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.45 by 6...
Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne'...
The BMP kit runs on Bio-Techne's Ella™, a benchtop automated immunoassay platform leveraging Bio-Techne's R&D Syste...
Deutsche Bank analyst Justin Bowers maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $85 to $82.